Abstract:Bacillus licheniformis produces several classes of antimicrobial substances, including bacteriocins, which are peptides or proteins with different structural composition and molecular mass: ribosomally synthesized by bacteria (1.4-20 kDa), non-ribosomally synthesized peptides and cyclic lipopeptides (0.8-42 kDa) and exopolysaccharides (>1000 kDa). Different bacteriocins act against Gram-positive or Gram-negative bacteria, fungal pathogens and amoeba cells. The main mechanisms of bacteriocin lytic activity include interaction of peptides with membranes of target cells resulting in structural alterations, pore-forming, and inhibition of cell wall biosynthesis. DNase and RNase activity for some bacteriocines are also postulated. Non-ribosomal peptides are synthesized by special non-ribosomal multimodular peptide synthetases and contain unnatural amino acids or fatty acids. Their harmful effect is due to their ability to form pores in biological membranes, destabilize lipid packaging, and disrupt the peptidoglycan layer. Lipopeptides, as biosurfactants, are able to destroy bacterial biofilms. Secreted polysaccharides are high molecular weight compounds, composed of repeated units of sugar moieties attached to a carrier lipid. Their antagonistic action was revealed in relation to bacteria, viruses, and fungi. Exopolysaccharides also inhibit the formation of biofilms by pathogenic bacteria and prevent their colonization on various surfaces. However, mechanism of the harmful effect for many secreted antibacterial substances remains unknown. The antimicrobial activity for most substances has been studied in vitro only, but some substances have been characterized in vivo and they have found practical applications in medicine and veterinary. The cyclic lipopeptides that have surfactant properties are used in some industries. In this review, special attention is paid to the antimycobacterials produced by B. licheniformis as a possible approach to combat multidrug-resistant and latent tuberculosis. In particular, licheniformins and bacitracins have shown strong antimycobacterial activity. However, the medical application of some antibacterials with promising in vitro antimycobacterial activity has been limited by their toxicity to animals and humans. As such, similar to the enhancement in the antimycobacterial activity of natural bacteriocins achieved using genetic engineering, the reduction in toxicity using the same approach appears feasible. The unique capability of B. licheniformis to synthesize and produce a range of different antibacterial compounds means that this organism can act as a natural universal vehicle for antibiotic substances in the form of probiotic cultures and strains to combat various types of pathogens, including mycobacteria.

Bacillus subtilis engineered for topical delivery of an antifungal agent

Fermentation process and kinetics of novel antifungal antibiotic production

Molecular insights into the antifungal mechanism of bacilysin

Feasibility of engineered Bacillus subtilis for use as a microbiome‐based topical drug delivery platform

Enhanced Production of Antifungal Lipopeptide Iturin A by Bacillus Amyloliquefaciens LL3 Through Metabolic Engineering and Culture Conditions Optimization

Generation of tetramycin B derivative with improved pharmacological property based on pathway engineering

Fungal Insecticidal Activity Elevated by Non-Risky Markerless Overexpression of an Endogenous Cysteine-Free Protein Gene in Beauveria Bassiana.

Mycosubtilin Overproduction by Bacillus subtilis BBG100 Enhances the Organism's Antagonistic and Biocontrol Activities

Insights into the antifungal mechanism of Bacillus subtilis cyclic lipopeptide iturin A mediated by potassium ion channel

Metabolic Engineering of Bacillus Subtilis 168 for the Utilization of Arabinose to Synthesize the Antifungal Lipopeptide Fengycin

Heterologous coexpression of Vitreoscilla hemoglobin and Bacillus megaterium glucanase in Streptomyces lydicus A02 enhanced its production of antifungal metabolites

BAC cloning and heterologous expression of a giant biosynthetic gene cluster encoding antifungal neotetrafibricin in streptomyces rubrisoli

Engineered biosynthesis of pimaricin derivatives with improved antifungal activity and reduced cytotoxicity

Structure Modification of an Antibiotic: by Engineering the Fusaricidin Bio-Synthetase A in Paenibacillus Polymyxa

Enhancement of fungichromin production of Streptomyces sp. WP-1 by genetic engineering

Modular metabolic engineering of Bacillus amyloliquefaciens for high-level production of green biosurfactant iturin A

Bacillus licheniformis: A Producer of Antimicrobial Substances, including Antimycobacterials, Which Are Feasible for Medical Applications

Industrial Production of Antibiotics in Fungi: Current State, Deciphering the Molecular Basis of Classical Strain Improvement and Increasing the Production of High-Yielding Strains by the Addition of Low-Molecular Weight Inducers

Integrated Biofilm Modification and Transcriptional Analysis for Improving Fengycin Production in Bacillus amyloliquefaciens

Engineering of a Genome-Reduced Strain Bacillus Amyloliquefaciens for Enhancing Surfactin Production

Living Bacterial Microneedles for Fungal Infection Treatment